1. Home
  2. SLVM vs SNDX Comparison

SLVM vs SNDX Comparison

Compare SLVM & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sylvamo Corporation

SLVM

Sylvamo Corporation

HOLD

Current Price

$50.59

Market Cap

1.9B

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.59

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLVM
SNDX
Founded
1898
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Paper
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.7B
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
SLVM
SNDX
Price
$50.59
$20.59
Analyst Decision
Buy
Strong Buy
Analyst Count
2
12
Target Price
$54.00
$36.92
AVG Volume (30 Days)
351.4K
2.0M
Earning Date
11-07-2025
11-03-2025
Dividend Yield
3.53%
N/A
EPS Growth
N/A
N/A
EPS
4.36
N/A
Revenue
$3,431,000,000.00
$111,304,000.00
Revenue This Year
N/A
$620.14
Revenue Next Year
N/A
$115.42
P/E Ratio
$11.68
N/A
Revenue Growth
N/A
595.65
52 Week Low
$37.52
$8.58
52 Week High
$87.33
$21.43

Technical Indicators

Market Signals
Indicator
SLVM
SNDX
Relative Strength Index (RSI) 63.13 63.36
Support Level $49.63 $19.72
Resistance Level $51.94 $21.43
Average True Range (ATR) 1.33 0.91
MACD 0.08 -0.10
Stochastic Oscillator 68.97 73.08

Price Performance

Historical Comparison
SLVM
SNDX

About SLVM Sylvamo Corporation

Sylvamo Corp is an uncoated papers company with a broad portfolio of top-tier brands and low-cost, large-scale paper mills, it produces uncoated freesheet (UFS) for paper products such as cut size and offset paper, as well as market pulp. The company offers Copy and Printer papers, Commercial Printing papers, Converting papers and Specialty papers. It operates in three geographical segments: Europe, Latin America, and North America. Key revenue is generated from North America.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: